abstract |
This invention relates to 1,3,4-thiadiazoles and 1,3,4-Oxadiazoles of formula (I), which are useful as antagonists of αvβ3 and related integrin receptors, to pharmaceutical compositions containing such compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angioginic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions, including their enantiomeric, diastereomeric, pharmaceutically acceptable salt or prodrug forms thereof wherein R1 is selected from formulas (a), (b), (c), (d), (e), (f) or (g); U, V, G, W, X, R20 are as defined in the application. |